Banwell Brenda, Ghezzi Angelo, Bar-Or Amit, Mikaeloff Yann, Tardieu Marc
Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
Lancet Neurol. 2007 Oct;6(10):887-902. doi: 10.1016/S1474-4422(07)70242-9.
The onset of multiple sclerosis (MS) in childhood poses diagnostic and therapeutic challenges, particularly if the symptoms of the first demyelinating event resemble acute disseminated encephalomyelitis (ADEM). MRI is an invaluable diagnostic tool but it lacks the specificity to distinguish ADEM from the first attack of MS. Advanced MRI techniques might have the required specificity to reveal whether the loss of integrity in non-lesional tissue occurs as a fundamental feature of MS. Although the onset of MS in childhood typically predicts a favourable short-term prognosis, some children are severely disabled, either physically or cognitively, and more than 50% are predicted to enter the secondary-progressive phase of the disease by the age of 30 years. Immunomodulatory therapies for MS and their safe application in children can improve long-term prognosis. Genetic and environmental factors, such as viral infection, might be uniquely amenable to study in paediatric patients with MS. Understanding the immunological consequences of these putative exposures will shed light on the early pathological changes in MS.
儿童多发性硬化症(MS)的发病带来了诊断和治疗方面的挑战,尤其是如果首次脱髓鞘事件的症状类似于急性播散性脑脊髓炎(ADEM)。磁共振成像(MRI)是一种非常有价值的诊断工具,但它缺乏区分ADEM和MS首次发作的特异性。先进的MRI技术可能具有所需的特异性,以揭示非病变组织完整性丧失是否作为MS的基本特征出现。虽然儿童期MS的发病通常预示着良好的短期预后,但一些儿童会出现严重的身体或认知残疾,预计超过50%的儿童到30岁时会进入疾病的继发进展期。MS的免疫调节疗法及其在儿童中的安全应用可以改善长期预后。遗传和环境因素,如病毒感染,可能特别适合在患有MS的儿科患者中进行研究。了解这些假定暴露的免疫后果将有助于揭示MS早期的病理变化。